Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Impact of incorporating ABCB1 and CYP4F2 polymorphisms in a pharmacogenetics-guided warfarin dosing algorithm for the Brazilian population

Full text
Author(s):
Tavares, Leticia C. [1] ; Duarte, Nubia E. [2] ; Marcatto, Leiliane R. [1] ; Soares, Renata A. G. [1] ; Krieger, Jose E. [1] ; Pereira, Alexandre C. [1] ; Junior Lima Santos, Paulo Caleb [1, 3]
Total Authors: 7
Affiliation:
[1] Univ Sao Paulo, Fac Med FMUSP, Heart Inst InCor, Lab Genet & Mol Cardiol, Sao Paulo, SP - Brazil
[2] Univ Nacl Colombia, Dept Math & Stat, Manizales, Caldas - Colombia
[3] Univ Fed Sao Paulo UNIFESP, Escola Paulista Med, Dept Pharmacol, Sao Paulo, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY; v. 74, n. 12, p. 1555-1566, DEC 2018.
Web of Science Citations: 2
Abstract

PurposeInterpatient variation of warfarin dose requirements may be explained by genetic variations and general and clinical factors. In this scenario, diverse population-calibrated dosing algorithms, which incorporate the main warfarin dosing influencers, have been widely proposed for predicting supposed warfarin maintenance dose, in order to prevent and reduce adverse events. The aim of the present study was to evaluate the impact of the inclusion of ABCB1 c.3435C>T and CYP4F2 c.1297G>A polymorphisms as additional covariates in a previously developed pharmacogenetic-based warfarin dosing algorithm calibrated for the Brazilian population.MethodsTwo independent cohorts of patients treated with warfarin (n=832 and n=133) were included for derivation and replication of the algorithm, respectively. Genotyping of ABCB1 c.3435C>T and CYP4F2 c.1297G>A polymorphisms was performed by polymerase chain reaction followed by melting curve analysis and TaqMan (R) assay, respectively. A multiple linear regression was performed for the warfarin stable doses as a dependent variable, considering clinical, general, and genetic data as covariates.ResultsThe inclusion of ABCB1 and CYP4F2 polymorphisms was able to improve the algorithm's coefficient of determination (R-2) by 2.6%. In addition, the partial determination coefficients of these variants revealed that they explained 3.6% of the warfarin dose variability. We also observed a marginal improvement of the linear correlation between observed and predicted doses (from 59.7 to 61.4%).ConclusionAlthough our study indicates that the contribution of the combined ABCB1 and CYP4F2 genotypes in explaining the overall variability in warfarin dose is not very large, we demonstrated that these pharmacogenomic data are statistically significant. However, the clinical relevance and cost-effective impact of incorporating additional variants in warfarin dosing algorithms should be carefully evaluated. (AU)

FAPESP's process: 16/22507-8 - Impact assessment of the inclusion of ABCB1 and CYP4F2 genes polymorphisms in pharmacogenetic-guided algorithm for personalized warfarin dosing
Grantee:Letícia Camargo Tavares
Support Opportunities: Scholarships in Brazil - Master
FAPESP's process: 16/23454-5 - Evaluation of a pharmacogenetic-based warfarin dosing algorithm in patients without stable dose
Grantee:Leiliane Rodrigues Marcatto
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 13/09295-3 - Pharmacogenetic of cardiovascular system drugs focusing on implementation
Grantee:Paulo Caleb Júnior de Lima Santos
Support Opportunities: Research Grants - Young Investigators Grants